Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 06:30PM GMT
Release Date Price: €21 (-0.94%)
Jackson Lowrie;Investment Banking Associate;JP Morgan

Good morning. My name is Jackson Lowrie, and I'm a member of the JPMorgan health care investment banking coverage team. It's my pleasure to introduce you to Jack Khattar, the CEO of Supernus Pharmaceuticals.

And just as we do finish, there will be a breakout in Elizabethan C, which is just next door. So I'll pass over to Jack.

Jack A. Khattar
Supernus Pharmaceuticals, Inc. - Founder, President, CEO, Secretary & Director

Thank you, and good morning. Before I get started, just try to remind everyone about the forward-looking statements I will be making during this session and the Q&A session. So please check the SEC filings for all the risk factors associated with the business.

Very quickly, for those of you who may not be very familiar with us, Supernus Pharmaceuticals actually has been around for more than 25 years. We operated for many years as a division of Shire Pharmaceuticals, so from 1997 until 2005, and then we spun out of Shire at the end of '05

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot